| 刘光世,李 涛,李 鹏,张 旺,魏苏艳,刘连伟.腹腔热灌注化疗联合全身系统化疗对晚期胃癌腹膜转移患者细胞免疫功能、肿瘤标志物和肿瘤侵袭转移相关指标的影响[J].,2023,(8):1482-1486 |
| 腹腔热灌注化疗联合全身系统化疗对晚期胃癌腹膜转移患者细胞免疫功能、肿瘤标志物和肿瘤侵袭转移相关指标的影响 |
| Effect of Hyperthermic Intraperitoneal Chemotherapy Combined with Neoadjuvant Intraperitoneal-Systemic Chemotherapy on Cellular Immune Function, Tumor Markers and Tumor Invasion Metastasis Related Indicators in Patients with Peritoneal Metastasis of Advanced Gastric Cancer |
| 投稿时间：2022-09-27 修订日期：2022-10-23 |
| DOI：10.13241/j.cnki.pmb.2023.08.016 |
| 中文关键词: 晚期胃癌 腹膜转移 全身系统化疗 腹腔热灌注化疗 细胞免疫功能 肿瘤标志物 侵袭转移 |
| 英文关键词: Advanced gastric cancer Peritoneal metastasis Neoadjuvant intraperitoneal-systemic chemotherapy Hyperthermic intraperitoneal chemotherapy Cellular immune function Tumor markers Invasion metastasis |
| 基金项目:新疆维吾尔自治区自然科学基金面上项目（2021D01C185） |
|
| 摘要点击次数: 564 |
| 全文下载次数: 257 |
| 中文摘要: |
| 摘要 目的：探讨腹腔热灌注化疗（HIPEC）联合全身系统化疗（NIPS）对晚期胃癌腹膜转移患者细胞免疫功能、肿瘤标志物和肿瘤侵袭转移相关指标的影响。方法：选取2019年6月至2022年1月在新疆医科大学第一附属医院胃肠外科住院治疗的116例晚期胃癌腹膜转移患者，按照随机数字表法分为观察组和对照组，各58例。对照组患者接受NIPS，观察组患者接受HIPEC联合NIPS。观察两组疗效、生存率和不良反应情况，对比两组细胞免疫功能、肿瘤标志物和肿瘤侵袭转移相关指标变化情况。结果：观察组的临床总有效率（68.97%）高于对照组（50.00%）（P<0.05）。两组治疗后CD3+、CD4+、CD4+/CD8+下降，但观察组高于对照组（P<0.05）。CD8+升高，但观察组低于对照组（P<0.05）。两组治疗后癌胚抗原（CEA）、糖类抗原19-9（CA199）、糖类抗原125（CA125）下降，但观察组低于对照组（P<0.05）。两组治疗后内皮生长因子（VEGF）、基质金属蛋白酶-2（MMP-2）和基质金属蛋白酶-9（MMP-9）下降，但观察组低于对照组（P<0.05）。观察组的6个月、9个月、12个月生存率均高于对照组（P<0.05）。两组不良反应发生率对比无差异（P>0.05）。结论：HIPEC联合NIPS用于治疗晚期胃癌腹膜转移患者，可改善患者细胞免疫功能，调节肿瘤标志物和肿瘤侵袭转移相关指标水平，提高生存率。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of hyperthermic intraperitoneal chemotherapy (HIPEC) combined with neoadjuvant intraperitoneal-systemic chemotherapy (NIPS) on cellular immune function, tumor markers and tumor invasion metastasis related indicators in patients with peritoneal metastasis of advanced gastric cancer. Methods: 116 patients with peritoneal metastasis of advanced gastric cancer who were hospitalized in the gastrointestinal surgery department of the First Affiliated Hospital of Xinjiang Medical University from June 2019 to January 2022 were selected, and they were divided into the observation group and the control group according to the random number table method, with 58 patients in each group. Patients in the control group received NIPS, and patients in the observation group received HIPEC combined with NIPS. The curative effect, survival rate and adverse reactions in the two groups were observed, and the changes of cellular immune function, tumor markers and tumor invasion metastasis related indicators in the two groups were compared. Results: The total clinical effective rate in the observation group (68.97%) was higher than (50.00%) in the control group (P<0.05). After treatment, the CD3+, CD4+, CD4+/CD8+ in the two groups decreased, but the observation group was higher than the control group(P<0.05). CD8+ increased, but the observation group was lower than the control group(P<0.05). Carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA199) and carbohydrate antigen 125 (CA125) in the two groups after treatment decreased, but the observation group was lower than the control group(P<0.05). Endothelial growth factor (VEGF), matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9(MMP-9) decreased in the two groups after treatment decreased, but the observation group was lower than the control group(P<0.05). The 6-month, 9-month and 12-month survival rates in the observation group were higher than those in the control group(P<0.05). There was no difference in the incidence of adverse reactions in the two groups(P>0.05). Conclusion: HIPEC combined with NIPS can improve the cellular immune function of patients with peritoneal metastasis of advanced gastric cancer, regulate the level of tumor markers and tumor invasion and metastasis related indicators, and improve the survival rate. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
